US54948U1051 - Common Stock
NASDAQ:LHDX (10/4/2022, 7:00:03 PM)+0.03 (+2.56%)
|GICS Sector||Health Care|
|GICS Industry||Health Care Equipment & Supplies|
|Earnings (Last)||08-15 2022-08-15/amc||Earnings (Next)||11-09 2022-11-09|
|Ins Owners||3.37%||Inst Owners||56.92%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Lucira Health, Inc. provides DNA testing services for medical, forensics, chemical, industrial, and agricultural applications. The company is headquartered in Emeryville, California and currently employs 219 full-time employees. The company went IPO on 2021-02-05. The firm is focused on the development and commercialization of transformative and infectious disease test kits. The firm has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and test kit that is powered by two AA batteries and fit in the palm of a hand. Its initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications. The company has developed LUCIRA COVID-19 All-In-One Test Kit (COVID-19 test kit), is a single-use, molecular in vitro diagnostic test that has an analytical sensitivity to detect the SARS-CoV-2 virus. The test is authorized for prescription at-home use.
LUCIRA HEALTH INC
1412 62nd Street
Emeryville CALIFORNIA 94608
CEO: Erik T. Engelson
Study Reveals Lucira’s Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexually Transmitted Infections...
Study Reveals Lucira’s Testing Assays Offer a 98% Accuracy Rate in Detecting Both Sexually Transmitted Infections
EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the...
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical...
Here you can normally see the latest stock twits on LHDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.